Neuromodulation devices for heart failure
View Full Paper
Ask AI
Bookmark
Share
Key result
Baroreflex activation therapy is FDA-approved for HFrEF while vagal and spinal cord stimulation remain investigational.
Why the study?
Autonomic imbalance with sympathetic dominance is a critical determinant of chronic HFrEF pathophysiology, leading to increasing interest in device-based neuromodulation strategies targeting the cardiac autonomic nervous system.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Provides approved autonomic modulation option for select HFrEF patients; leaves open comparative efficacy of other neuromodulation strategies.
Structured PICO
P
Population
Patients with chronic heart failure with reduced ejection fraction (HFrEF)
I
Intervention
Device-based neuromodulation including cervical vagal nerve stimulation (cVNS), baroreflex activation therapy (BAT), and spinal cord stimulation (SCS)
Device-based neuromodulation strategies targeting autonomic imbalance in HFrEF show physiological promise, with baroreflex activation therapy achieving clinical approval and others under active investigation.
Limitations
- Clinical use and technological innovations largely outrun scientific understanding of the dose-response relationship of electrical neuromodulation.
- The highly integrated and dynamic behavior of the autonomic nervous system makes determining optimal stimulation protocols difficult.
Cite This Study
Dusi et al. (2022) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Device-based neuromodulation (cVNS, BAT, SCS) was evaluated. Baroreflex activation therapy has been approved by the FDA for patients with HFrEF, while cervical vagal nerve stimulation and spinal cord stimulation remain investigational.
View Full Paper
Ask AI
Bookmark
Share